The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma-Reference-Cited by-同舟云学术

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Published:2015-07-16 Issue:3 Volume:126 Page:328-335
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Witzig Thomas E.¹^ORCID,Reeder Craig²,Han Jing Jing¹,LaPlant Betsy³,Stenson Mary¹,Tun Han W.⁴,Macon William⁵,Ansell Stephen M.¹,Habermann Thomas M.¹,Inwards David J.¹,Micallef Ivana N.¹,Johnston Patrick B.¹,Porrata Luis F.¹,Colgan Joseph P.¹,Markovic Svetomir¹,Nowakowski Grzegorz S.¹,Gupta Mamta¹

Affiliation:

1. Division of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN;

2. Division of Hematology, Department of Medicine, Mayo Clinic Scottsdale, Scottsdale, AZ;

3. Division of Biomedical Statistics and Bioinformatics, Department of Health Sciences Research, Mayo Clinic Rochester, Rochester, MN;

4. Division of Hematology, Department of Medicine, Mayo Clinic Jacksonville, Jacksonville, FL; and

5. Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN

Abstract

Key Points The mTOR pathway is constitutively activated in the TCL cells and is responsible for TCL proliferation. This is first trial to demonstrate that mTORC1 inhibitors (everolimus) have substantial antitumor activity (44% overall response rate) in patients with relapsed TCL.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/3/328/1390738/328.pdf

Reference35 articles.

1. Cancer statistics, 2015.;Siegel;CA Cancer J Clin,2015

2. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.;Goy;J Clin Oncol,2013

3. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.;Wang;N Engl J Med,2013

4. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.;Byrd;N Engl J Med,2013

5. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.;O’Connor;J Clin Oncol,2011

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DEPTOR levels in patients with mycosis fungoides;Dermatologica Sinica;2024-09-12

2. Kinases Inhibitors as New Therapeutic Opportunities in Cutaneous T-Cell Lymphoma;Kinases and Phosphatases;2024-08-28

3. Mutations in Ras homolog family member A in patients with peripheral T-cell lymphoma and implications for personalized medicine;Cancer Biology & Medicine;2024-08-09

4. ThermoTargetMiner as a proteome integral solubility alteration target database for prospective drugs against lung cancer;2024-08-06

5. Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial;Nature Medicine;2024-06-17